The FINANCIAL — Merck on June 13 announced results from two Phase 3 studies evaluating MK-1293, Merck’s investigational, follow-on biologic insulin glargine candidate for the treatment of people with ...

Insulin remains one of the most important treatments for people living with diabetes. Whether someone has Type 1 diabetes or advanced Type 2 diabetes, insulin therapy helps control blood sugar levels, ...

The FINANCIAL — Data from secondary analyses of Phase III clinical trials showed that ABASAGLAR (insulin glargine), Eli Lilly and Company and Boehringer Ingelheim’s biosimilar insulin glargine, ...

Sanofi’s Lantus, its most commonly prescribed insulin, will sell for $35 a month through GoodRx Holdings Inc. in a deal that signals the drug-discount site’s growing business with large pharma ...

After nearly seven months and two prior recalls, Viatris continues to be vexed by labeling issues on its biosimilar to Sanofi’s diabetes blockbuster Lantus. Viatris’ Mylan this week said it was once ...

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, today announced it is working with Sanofi (NASDAQ: SNY), a global leader in ...

The follow-on or copycat insulin glargine product Basaglar (Lilly) is similar to brand-name Lantus (Sanofi) in terms of efficacy and safety for the treatment of type 2 diabetes, but Basaglar cost less ...

Overview: Insulin glargine is a long-acting insulin used to lower blood sugar levels in people with diabetes. It helps get sugar into your cells, so your body can use it for energy. The most common ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adults with type 1 diabetes using insulin glargine had ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved insulin glargine-aglr, a second biosimilar to Sanofi’s insulin glargine, to improve glycemic ...